Agrochemical giant Bayer and attorneys representing cancer patients have announced a proposed $7.25 billion settlement. A proposal aimed at resolving thousands of US lawsuits alleging that the company failed to warn consumers that its weedkiller Roundup could cause cancer. The agreement comes as the US Supreme Court prepares to hear arguments in April on whether the Environmental Protection Agency’s approval of Roundup without a cancer warning should override state-level failure-to-warn claims. While the pending Supreme Court case would not be directly affected by the proposed settlement, the deal would reduce legal uncertainty for both sides. Litigants would be guaranteed compensation even if the Court rules in Bayer’s favor, and Bayer would limit its exposure if the ruling goes against it.
Bayer, which acquired Monsanto in 2018, continues to dispute claims that glyphosate, Roundup’s key ingredient, causes non-Hodgkin lymphoma. However, the company acknowledges that years of litigation have weighed heavily on its operations and financial outlook. CEO Bill Anderson described the settlement as a pathway toward resolving prolonged legal uncertainty. The proposal, filed in Missouri’s St. Louis Circuit Court, where many cases have originated, still requires judicial approval.
Settelment payouts to the sick would vary
Roughly 200,000 claims related to Roundup have been filed against Bayer, including more than 125,000 lawsuits since 2015. Jury outcomes have been mixed, with 13 verdicts in Bayer’s favor and 11 for plaintiffs, including a $2.1 billion grant in Georgia last year. Other claims have been settled separately, including two recent agreements covering approximately 77,000 cases. The new nationwide settlement seeks to address most remaining lawsuits, as well as future claims from individuals exposed to Roundup before the agreement date. Bayer has reserved the right to cancel the deal if too many plaintiffs opt out, though it has not specified the threshold.
Under the proposal, Bayer would fund annual payments over up to 21 years, totaling as much as $7.25 billion. Compensation would depend on factors such as the claimant’s level of exposure, age at diagnosis, and severity of illness. For example, younger agricultural or industrial workers diagnosed with aggressive non-Hodgkin lymphoma could receive an average of $165,000. Meanwhile older residential users with less aggressive forms might receive between $10,000 and $20,000. Attorney Christopher Seeger, representing claimants under the agreement, described the settlement as an effort to provide meaningful compensation for both current and future patients. However, some attorneys representing plaintiffs have criticized the proposed payouts as insufficient, and some expect many clients to opt out.
Bayer gets Trump’s backing in Court
Amid litigation, Bayer has removed glyphosate from Roundup products sold in the US residential lawn and garden market, though the chemical remains in agricultural formulations. Glyphosate is commonly used alongside genetically modified seeds designed to withstand the herbicide, allowing farmers to increase yields and reduce soil disruption. Although some studies have linked glyphosate to cancer, the EPA maintains that it is unlikely to be carcinogenic when used as directed. Hence, federal labeling requirements do not include a cancer warning.
Bayer argues that federal pesticide laws preempt states from imposing additional labeling requirements, and therefore state-level failure-to-warn lawsuits should not proceed. The company has taken this position to the Supreme Court in an appeal of a Missouri case that awarded damages to a man who developed non-Hodgkin lymphoma after using Roundup. The Trump administration has supported Bayer’s argument, reversing the stance taken under President Biden. Meanwhile, Bayer has lobbied state legislatures to pass laws shielding pesticide manufacturers from certain state lawsuits when products comply with federal labeling standards. North Dakota and Georgia have already enacted such protections.
Reference
Lieb, D. A. (2026, 17 February). Bayer strikes $7.25 billion deal to settle Roundup cancer lawsuits. AP News. https://apnews.com/article/bayer-monsanto-roundup-lawsuits-settlement-154ad7c6bdff3a91b06c4e327321160b